This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Congratulates Lee Clough On Winning Award From American Society For Apheresis

NEW YORK, March 31, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Lee Clough, RN, HP (ASCP), Director of Clinical Affairs & Apheresis for Progenitor Cell Therapy (PCT), a wholly-owned subsidiary of NeoStem, has been awarded the SHS Award from the American Society for Apheresis (ASFA). Ms. Clough will be presented with the award at the ASFA Annual Business Meeting Luncheon in San Francisco, CA on April 4, 2014.

The SHS award is given to an allied health member who has demonstrated sincere commitment to apheresis (a medical technology in which the blood of a patient is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation), and who has emerged as a leader and role model in the field. The SHS Award (short for The Society for Hemapheresis Specialists) was the first national organization in the United States which provided a forum for the professional development of technical specialists in the field of apheresis. This award commemorates the pioneering efforts of SHS which have culminated in the high standards and sophistication which characterize the field of American apheresis.

"I am excited and proud to be honored with this award by my peers for a job I love to do," said Ms. Clough. "I am committed to educating people about apheresis and training technicians to do it well. The job comes with a certain satisfaction in knowing that you are training people who will be out in the field saving lives."

Ms. Clough joined PCT in 2009 and is an integral part of PCT's cellular therapy business, as well as NeoStem's adult stem cell and cord blood collection, processing and storage business (NeoStem Family Storage). She regularly oversees the apheresis portion of PCT's clients' specific cellular therapy projects, writes and updates the company's apheresis procedures, trains staff in apheresis collection, and assists PCT's clients in assessing and training their collection sites for their clinical trial programs. She began her apheresis career at Children's Hospital of Philadelphia and, prior to her time with PCT, she worked at Inova, managing five donor centers and a therapeutic apheresis center, and at Dendreon as an apheresis specialist. She earned her B.S.N. at the University of Delaware.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs